Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 138

1.

Gata3 Immunohistochemical Staining is A Useful Marker for Metastatic Breast Carcinoma in Fine Needle Aspiration Specimens.

Shield PW, Crouch SJ, Papadimos DJ, Walsh MD.

J Cytol. 2018 Apr-Jun;35(2):90-93. doi: 10.4103/JOC.JOC_132_17.

2.

Identification of metastatic papillary thyroid carcinoma in FNA specimens using thyroid peroxidase immunohistochemistry.

Shield PW, Crouch SJ, Papadimos DJ, Walsh MD.

Cytopathology. 2018 Mar 6. doi: 10.1111/cyt.12531. [Epub ahead of print]

PMID:
29508480
3.

Combining blinatumomab with targeted therapy for BCR-ABL mutant relapsed/refractory acute lymphoblastic leukemia.

Hanif A, Wang ES, Thompson JE, Baron JI, Walsh MD, Griffiths EA.

Leuk Lymphoma. 2017 Dec 18:1-3. doi: 10.1080/10428194.2017.1411595. [Epub ahead of print] No abstract available.

PMID:
29251203
4.

Promoting Limb Salvage through Multi-Disciplinary Care of the Diabetic Patient.

Salvo NL, Walsh MD, Brewster LP.

Curr Treat Options Cardiovasc Med. 2017 Jul;19(7):55. doi: 10.1007/s11936-017-0547-1. Review.

PMID:
28567565
5.

Modeling Enzyme Processivity Reveals that RNA-Seq Libraries Are Biased in Characteristic and Correctable Ways.

Archer N, Walsh MD, Shahrezaei V, Hebenstreit D.

Cell Syst. 2016 Nov 23;3(5):467-479.e12. doi: 10.1016/j.cels.2016.10.012. Epub 2016 Nov 10.

6.

Tumor testing to identify lynch syndrome in two Australian colorectal cancer cohorts.

Buchanan DD, Clendenning M, Rosty C, Eriksen SV, Walsh MD, Walters RJ, Thibodeau SN, Stewart J, Preston S, Win AK, Flander L, Ouakrim DA, Macrae FA, Boussioutas A, Winship IM, Giles GG, Hopper JL, Southey MC, English D, Jenkins MA.

J Gastroenterol Hepatol. 2017 Feb;32(2):427-438. doi: 10.1111/jgh.13468.

7.

Germline mutations in PMS2 and MLH1 in individuals with solitary loss of PMS2 expression in colorectal carcinomas from the Colon Cancer Family Registry Cohort.

Rosty C, Clendenning M, Walsh MD, Eriksen SV, Southey MC, Winship IM, Macrae FA, Boussioutas A, Poplawski NK, Parry S, Arnold J, Young JP, Casey G, Haile RW, Gallinger S, Le Marchand L, Newcomb PA, Potter JD, DeRycke M, Lindor NM, Thibodeau SN, Baron JA, Win AK, Hopper JL, Jenkins MA, Buchanan DD; Colon Cancer Family Registry Cohort.

BMJ Open. 2016 Feb 19;6(2):e010293. doi: 10.1136/bmjopen-2015-010293.

8.

Lynch syndrome and cervical cancer.

Antill YC, Dowty JG, Win AK, Thompson T, Walsh MD, Cummings MC, Gallinger S, Lindor NM, Le Marchand L, Hopper JL, Newcomb PA, Haile RW, Church J, Tucker KM, Buchanan DD, Young JP, Winship IM, Jenkins MA.

Int J Cancer. 2015 Dec 1;137(11):2757-61. doi: 10.1002/ijc.29641. Epub 2015 Jul 14.

9.

High prevalence of mismatch repair deficiency in prostate cancers diagnosed in mismatch repair gene mutation carriers from the colon cancer family registry.

Rosty C, Walsh MD, Lindor NM, Thibodeau SN, Mundt E, Gallinger S, Aronson M, Pollett A, Baron JA, Pearson S, Clendenning M, Walters RJ, Nagler BN, Crawford WJ, Young JP, Winship I, Win AK, Hopper JL, Jenkins MA, Buchanan DD.

Fam Cancer. 2014 Dec;13(4):573-82. doi: 10.1007/s10689-014-9744-1.

10.

Re: Microsatellite instability and BRAF mutation testing in colorectal cancer prognostication.

Rosty C, Williamson EJ, Clendenning M, Walters RJ, Walsh MD, Win AK, Jenkins MA, Hopper JL, Winship I, Southey MC, Giles GG, English DR, Buchanan DD.

J Natl Cancer Inst. 2014 Aug 11;106(8). pii: dju180. doi: 10.1093/jnci/dju180. Print 2014 Aug. No abstract available.

PMID:
25114271
11.

Reply to J. Moline et al.

Buchanan DD, Tan YY, Walsh MD, Clendenning M, Metcalf AM, Ferguson K, Arnold ST, Thompson BA, Lose FA, Parsons MT, Walters RJ, Pearson SA, Cummings M, Oehler MK, Blomfield PB, Quinn MA, Kirk JA, Stewart CJ, Obermair A, Young JP, Webb PM, Spurdle AB.

J Clin Oncol. 2014 Jul 20;32(21):2278-9. doi: 10.1200/JCO.2014.55.8213. Epub 2014 Jun 9. No abstract available.

PMID:
24912891
12.

Role of tumour molecular and pathology features to estimate colorectal cancer risk for first-degree relatives.

Win AK, Buchanan DD, Rosty C, MacInnis RJ, Dowty JG, Dite GS, Giles GG, Southey MC, Young JP, Clendenning M, Walsh MD, Walters RJ, Boussioutas A, Smyrk TC, Thibodeau SN, Baron JA, Potter JD, Newcomb PA, Le Marchand L, Haile RW, Gallinger S, Lindor NM, Hopper JL, Ahnen DJ, Jenkins MA.

Gut. 2015 Jan;64(1):101-10. doi: 10.1136/gutjnl-2013-306567. Epub 2014 Mar 10.

13.

GATA3: a promising marker for metastatic breast carcinoma in serous effusion specimens.

Shield PW, Papadimos DJ, Walsh MD.

Cancer Cytopathol. 2014 Apr;122(4):307-12. doi: 10.1002/cncy.21393. Epub 2014 Jan 13.

14.

Tumor mismatch repair immunohistochemistry and DNA MLH1 methylation testing of patients with endometrial cancer diagnosed at age younger than 60 years optimizes triage for population-level germline mismatch repair gene mutation testing.

Buchanan DD, Tan YY, Walsh MD, Clendenning M, Metcalf AM, Ferguson K, Arnold ST, Thompson BA, Lose FA, Parsons MT, Walters RJ, Pearson SA, Cummings M, Oehler MK, Blomfield PB, Quinn MA, Kirk JA, Stewart CJ, Obermair A, Young JP, Webb PM, Spurdle AB.

J Clin Oncol. 2014 Jan 10;32(2):90-100. doi: 10.1200/JCO.2013.51.2129. Epub 2013 Dec 9.

15.

Scrotal abscess as initial presentation of squamous cell carcinoma.

Huen KH, Nourparvar P, Decaro JJ, Walsh MD, Issa MM, Ritenour CW.

Case Rep Urol. 2013;2013:807346. doi: 10.1155/2013/807346. Epub 2013 Sep 11.

16.

Immunophenotypic analysis of ovarian endometrioid adenocarcinoma: correlation with KRAS mutation and the presence of endometriosis.

Stewart CJ, Walsh MD, Budgeon CA, Crook ML, Buchanan DB.

Pathology. 2013 Oct;45(6):559-66. doi: 10.1097/PAT.0b013e3283650ad7.

PMID:
24018808
17.

Meta-analysis of inter-patient pharmacokinetic variability of liposomal and non-liposomal anticancer agents.

Schell RF, Sidone BJ, Caron WP, Walsh MD, White TF, Zamboni BA, Ramanathan RK, Zamboni WC.

Nanomedicine. 2014 Jan;10(1):109-17. doi: 10.1016/j.nano.2013.07.005. Epub 2013 Jul 24.

18.

Expression of MUC2, MUC5AC, MUC5B, and MUC6 mucins in colorectal cancers and their association with the CpG island methylator phenotype.

Walsh MD, Clendenning M, Williamson E, Pearson SA, Walters RJ, Nagler B, Packenas D, Win AK, Hopper JL, Jenkins MA, Haydon AM, Rosty C, English DR, Giles GG, McGuckin MA, Young JP, Buchanan DD.

Mod Pathol. 2013 Dec;26(12):1642-56. doi: 10.1038/modpathol.2013.101. Epub 2013 Jun 28.

19.

Germline Mutations in the Polyposis-Associated Genes BMPR1A, SMAD4, PTEN, MUTYH and GREM1 Are Not Common in Individuals with Serrated Polyposis Syndrome.

Clendenning M, Young JP, Walsh MD, Woodall S, Arnold J, Jenkins M, Win AK, Hopper JL, Sweet K, Gallinger S, Rosty C, Parry S, Buchanan DD.

PLoS One. 2013 Jun 21;8(6):e66705. doi: 10.1371/journal.pone.0066705. Print 2013.

20.

Association between hypermethylation of DNA repetitive elements in white blood cell DNA and early-onset colorectal cancer.

Walters RJ, Williamson EJ, English DR, Young JP, Rosty C, Clendenning M, Walsh MD, Parry S, Ahnen DJ, Baron JA, Win AK, Giles GG, Hopper JL, Jenkins MA, Buchanan DD.

Epigenetics. 2013 Jul;8(7):748-55. doi: 10.4161/epi.25178. Epub 2013 Jun 17.

21.

BRAFV600E immunohistochemistry facilitates universal screening of colorectal cancers for Lynch syndrome.

Toon CW, Walsh MD, Chou A, Capper D, Clarkson A, Sioson L, Clarke S, Mead S, Walters RJ, Clendenning M, Rosty C, Young JP, Win AK, Hopper JL, Crook A, von Deimling A, Jenkins MA, Buchanan DD, Gill AJ.

Am J Surg Pathol. 2013 Oct;37(10):1592-602. doi: 10.1097/PAS.0b013e31828f233d.

22.

PIK3CA activating mutation in colorectal carcinoma: associations with molecular features and survival.

Rosty C, Young JP, Walsh MD, Clendenning M, Sanderson K, Walters RJ, Parry S, Jenkins MA, Win AK, Southey MC, Hopper JL, Giles GG, Williamson EJ, English DR, Buchanan DD.

PLoS One. 2013 Jun 13;8(6):e65479. doi: 10.1371/journal.pone.0065479. Print 2013.

23.

Family history of colorectal cancer in BRAF p.V600E-mutated colorectal cancer cases.

Buchanan DD, Win AK, Walsh MD, Walters RJ, Clendenning M, Nagler B, Pearson SA, Macrae FA, Parry S, Arnold J, Winship I, Giles GG, Lindor NM, Potter JD, Hopper JL, Rosty C, Young JP, Jenkins MA.

Cancer Epidemiol Biomarkers Prev. 2013 May;22(5):917-26. doi: 10.1158/1055-9965.EPI-12-1211. Epub 2013 Mar 5.

24.

Lynch syndrome-associated breast cancers do not overexpress chromosome 11-encoded mucins.

Walsh MD, Cummings MC, Pearson SA, Clendenning M, Walters RJ, Nagler B, Hopper JL, Jenkins MA, Suthers GK, Goldblatt J, Tucker K, Gattas MR, Arnold JL, Parry S, Macrae FA, McGuckin MA, Young JP, Buchanan DD.

Mod Pathol. 2013 Jul;26(7):944-54. doi: 10.1038/modpathol.2012.232. Epub 2013 Feb 1.

25.

Colorectal carcinomas with KRAS mutation are associated with distinctive morphological and molecular features.

Rosty C, Young JP, Walsh MD, Clendenning M, Walters RJ, Pearson S, Pavluk E, Nagler B, Pakenas D, Jass JR, Jenkins MA, Win AK, Southey MC, Parry S, Hopper JL, Giles GG, Williamson E, English DR, Buchanan DD.

Mod Pathol. 2013 Jun;26(6):825-34. doi: 10.1038/modpathol.2012.240. Epub 2013 Jan 25.

26.

Detection of large scale 3' deletions in the PMS2 gene amongst Colon-CFR participants: have we been missing anything?

Clendenning M, Walsh MD, Gelpi JB, Thibodeau SN, Lindor N, Potter JD, Newcomb P, LeMarchand L, Haile R, Gallinger S; Colorectal Cancer Family Registry, Hopper JL, Jenkins MA, Rosty C, Young JP, Buchanan DD.

Fam Cancer. 2013 Sep;12(3):563-6. doi: 10.1007/s10689-012-9597-4.

27.

Improving identification of lynch syndrome patients: a comparison of research data with clinical records.

Tan YY, McGaughran J, Ferguson K, Walsh MD, Buchanan DD, Young JP, Webb PM, Obermair A, Spurdle AB; ANECS Group.

Int J Cancer. 2013 Jun 15;132(12):2876-83. doi: 10.1002/ijc.27978. Epub 2013 Jan 11.

28.

Plasma, tumor and tissue pharmacokinetics of Docetaxel delivered via nanoparticles of different sizes and shapes in mice bearing SKOV-3 human ovarian carcinoma xenograft.

Chu KS, Hasan W, Rawal S, Walsh MD, Enlow EM, Luft JC, Bridges AS, Kuijer JL, Napier ME, Zamboni WC, DeSimone JM.

Nanomedicine. 2013 Jul;9(5):686-93. doi: 10.1016/j.nano.2012.11.008. Epub 2012 Dec 6.

29.

Multiplicity and molecular heterogeneity of colorectal carcinomas in individuals with serrated polyposis.

Rosty C, Walsh MD, Walters RJ, Clendenning M, Pearson SA, Jenkins MA, Win AK, Hopper JL, Sweet K, Frankel WL, Aronson M, Gallinger S, Goldblatt J, Tucker K, Greening S, Gattas MR, Woodall S, Arnold J, Walker NI, Parry S, Young JP, Buchanan DD.

Am J Surg Pathol. 2013 Mar;37(3):434-42. doi: 10.1097/PAS.0b013e318270f748.

30.

Absence of PMS2 mutations in colon-CFR participants whose colorectal cancers demonstrate unexplained loss of MLH1 expression.

Clendenning M, Macrae FA, Walsh MD, Walters RJ, Thibodeau SN, Gunawardena SR, Potter JD, Haile RW, Gallinger S; Colorectal Cancer Family Registry, Hopper JL, Jenkins MA, Rosty C, Young JP, Buchanan DD.

Clin Genet. 2013 Jun;83(6):591-3. doi: 10.1111/cge.12011. Epub 2012 Sep 27. No abstract available.

31.

[Orbital invasion of a maxillary ameloblastoma].

Herwig MC, Fischer HP, Moore CE, Walsh MD, Olson JJ, Beitler JJ, Grossniklaus HE.

Ophthalmologe. 2013 Mar;110(3):251-4. doi: 10.1007/s00347-012-2622-z. German.

PMID:
22752627
32.

Body size and risk for colorectal cancers showing BRAF mutations or microsatellite instability: a pooled analysis.

Hughes LA, Williamson EJ, van Engeland M, Jenkins MA, Giles GG, Hopper JL, Southey MC, Young JP, Buchanan DD, Walsh MD, van den Brandt PA, Alexandra Goldbohm R, Weijenberg MP, English DR.

Int J Epidemiol. 2012 Aug;41(4):1060-72. Epub 2012 Apr 24.

PMID:
22531127
33.

Cancer risks for relatives of patients with serrated polyposis.

Win AK, Walters RJ, Buchanan DD, Jenkins MA, Sweet K, Frankel WL, de la Chapelle A, McKeone DM, Walsh MD, Clendenning M, Pearson SA, Pavluk E, Nagler B, Hopper JL, Gattas MR, Goldblatt J, George J, Suthers GK, Phillips KD, Woodall S, Arnold J, Tucker K, Field M, Greening S, Gallinger S, Aronson M, Perrier R, Woods MO, Green JS, Walker N, Rosty C, Parry S, Young JP.

Am J Gastroenterol. 2012 May;107(5):770-8. doi: 10.1038/ajg.2012.52. Epub 2012 Apr 24.

34.

Phenotype and polyp landscape in serrated polyposis syndrome: a series of 100 patients from genetics clinics.

Rosty C, Buchanan DD, Walsh MD, Pearson SA, Pavluk E, Walters RJ, Clendenning M, Spring KJ, Jenkins MA, Win AK, Hopper JL, Sweet K, Frankel WL, Aronson M, Gallinger S, Goldblatt J, Woodall S, Arnold J, Walker NI, Jass JR, Parry S, Young JP.

Am J Surg Pathol. 2012 Jun;36(6):876-82. doi: 10.1097/PAS.0b013e31824e133f.

35.

Pharmacokinetics and antitumor efficacy of XMT-1001, a novel, polymeric topoisomerase I inhibitor, in mice bearing HT-29 human colon carcinoma xenografts.

Walsh MD, Hanna SK, Sen J, Rawal S, Cabral CB, Yurkovetskiy AV, Fram RJ, Lowinger TB, Zamboni WC.

Clin Cancer Res. 2012 May 1;18(9):2591-602. doi: 10.1158/1078-0432.CCR-11-1554. Epub 2012 Mar 5.

36.

Immunohistochemical testing of conventional adenomas for loss of expression of mismatch repair proteins in Lynch syndrome mutation carriers: a case series from the Australasian site of the colon cancer family registry.

Walsh MD, Buchanan DD, Pearson SA, Clendenning M, Jenkins MA, Win AK, Walters RJ, Spring KJ, Nagler B, Pavluk E, Arnold ST, Goldblatt J, George J, Suthers GK, Phillips K, Hopper JL, Jass JR, Baron JA, Ahnen DJ, Thibodeau SN, Lindor N, Parry S, Walker NI, Rosty C, Young JP.

Mod Pathol. 2012 May;25(5):722-30. doi: 10.1038/modpathol.2011.209. Epub 2012 Feb 10.

37.

KRAS mutations in ovarian low-grade endometrioid adenocarcinoma: association with concurrent endometriosis.

Stewart CJ, Leung Y, Walsh MD, Walters RJ, Young JP, Buchanan DD.

Hum Pathol. 2012 Aug;43(8):1177-83. doi: 10.1016/j.humpath.2011.10.009. Epub 2012 Feb 2.

PMID:
22305241
38.

Using tumour pathology to identify people at high genetic risk of breast and colorectal cancers.

Hopper JL, Jenkins MA, Dowty JG, Dite GS, Apicella C, Keogh L, Win AK, Young JP, Buchanan D, Walsh MD, Rosty C, Baglietto L, Severi G, Phillips KA, Wong EM, Dobrovic A, Waring P, Winship I, Ramus SJ, Giles GG, Southey MC.

Pathology. 2012 Feb;44(2):89-98. doi: 10.1097/PAT.0b013e32834e8e5b. Review.

PMID:
22198256
39.

Quality assessment and correlation of microsatellite instability and immunohistochemical markers among population- and clinic-based colorectal tumors results from the Colon Cancer Family Registry.

Cicek MS, Lindor NM, Gallinger S, Bapat B, Hopper JL, Jenkins MA, Young J, Buchanan D, Walsh MD, Le Marchand L, Burnett T, Newcomb PA, Grady WM, Haile RW, Casey G, Plummer SJ, Krumroy LA, Baron JA, Thibodeau SN.

J Mol Diagn. 2011 May;13(3):271-81. doi: 10.1016/j.jmoldx.2010.12.004.

40.

Complex abdominal wall hernias: a new classification system and approach to management based on review of 133 consecutive patients.

Hadeed JG, Walsh MD, Pappas TN, Pestana IA, Tyler DS, Levinson H, Mantyh C, Jacobs DO, Lagoo-Deenadalayan SA, Erdmann D.

Ann Plast Surg. 2011 May;66(5):497-503. doi: 10.1097/SAP.0b013e3182145387.

PMID:
21451375
41.

Mutation deep within an intron of MSH2 causes Lynch syndrome.

Clendenning M, Buchanan DD, Walsh MD, Nagler B, Rosty C, Thompson B, Spurdle AB, Hopper JL, Jenkins MA, Young JP.

Fam Cancer. 2011 Jun;10(2):297-301. doi: 10.1007/s10689-011-9427-0.

42.

The role of intrathoracic free flaps for chronic empyema.

Walsh MD, Bruno AD, Onaitis MW, Erdmann D, Wolfe WG, Toloza EM, Levin LS.

Ann Thorac Surg. 2011 Mar;91(3):865-8. doi: 10.1016/j.athoracsur.2010.10.019.

PMID:
21353016
43.

Linkage to chromosome 2q32.2-q33.3 in familial serrated neoplasia (Jass syndrome).

Roberts A, Nancarrow D, Clendenning M, Buchanan DD, Jenkins MA, Duggan D, Taverna D, McKeone D, Walters R, Walsh MD, Young BW, Jass JR, Rosty C, Gattas M, Pelzer E, Hopper JL, Goldblatt J, George J, Suthers GK, Phillips K, Parry S, Woodall S, Arnold J, Tucker K, Muir A, Drini M, Macrae F, Newcomb P, Potter JD, Pavluk E, Lindblom A, Young JP.

Fam Cancer. 2011 Jun;10(2):245-54. doi: 10.1007/s10689-010-9408-8.

44.

Risk factors for colorectal cancer in patients with multiple serrated polyps: a cross-sectional case series from genetics clinics.

Buchanan DD, Sweet K, Drini M, Jenkins MA, Win AK, English DR, Walsh MD, Clendenning M, McKeone DM, Walters RJ, Roberts A, Pearson SA, Pavluk E, Hopper JL, Gattas MR, Goldblatt J, George J, Suthers GK, Phillips KD, Woodall S, Arnold J, Tucker K, Muir A, Field M, Greening S, Gallinger S, Perrier R, Baron JA, Potter JD, Haile R, Frankel W, de la Chapelle A, Macrae F, Rosty C, Walker NI, Parry S, Young JP.

PLoS One. 2010 Jul 16;5(7):e11636. doi: 10.1371/journal.pone.0011636.

45.

Lessons from Lynch syndrome: a tumor biology-based approach to familial colorectal cancer.

Buchanan DD, Roberts A, Walsh MD, Parry S, Young JP.

Future Oncol. 2010 Apr;6(4):539-49. doi: 10.2217/fon.10.16. Review.

46.

Lynch syndrome-associated breast cancers: clinicopathologic characteristics of a case series from the colon cancer family registry.

Walsh MD, Buchanan DD, Cummings MC, Pearson SA, Arnold ST, Clendenning M, Walters R, McKeone DM, Spurdle AB, Hopper JL, Jenkins MA, Phillips KD, Suthers GK, George J, Goldblatt J, Muir A, Tucker K, Pelzer E, Gattas MR, Woodall S, Parry S, Macrae FA, Haile RW, Baron JA, Potter JD, Le Marchand L, Bapat B, Thibodeau SN, Lindor NM, McGuckin MA, Young JP.

Clin Cancer Res. 2010 Apr 1;16(7):2214-24. doi: 10.1158/1078-0432.CCR-09-3058. Epub 2010 Mar 9.

47.

Phenotypic diversity in patients with multiple serrated polyps: a genetics clinic study.

Buchanan DD, Sweet K, Drini M, Jenkins MA, Win AK, Gattas M, Walsh MD, Clendenning M, McKeone D, Walters R, Roberts A, Young A, Hampel H, Hopper JL, Goldblatt J, George J, Suthers GK, Phillips K, Young GP, Chow E, Parry S, Woodall S, Tucker K, Muir A, Field M, Greening S, Gallinger S, Green J, Woods MO, Spaetgens R, de la Chapelle A, Macrae F, Walker NI, Jass JR, Young JP.

Int J Colorectal Dis. 2010 Jun;25(6):703-12. doi: 10.1007/s00384-010-0907-8. Epub 2010 Mar 6. Erratum in: Int J Colorectal Dis. 2010 Dec;25(12):1513-5.

48.

Risks of Lynch syndrome cancers for MSH6 mutation carriers.

Baglietto L, Lindor NM, Dowty JG, White DM, Wagner A, Gomez Garcia EB, Vriends AH; Dutch Lynch Syndrome Study Group, Cartwright NR, Barnetson RA, Farrington SM, Tenesa A, Hampel H, Buchanan D, Arnold S, Young J, Walsh MD, Jass J, Macrae F, Antill Y, Winship IM, Giles GG, Goldblatt J, Parry S, Suthers G, Leggett B, Butz M, Aronson M, Poynter JN, Baron JA, Le Marchand L, Haile R, Gallinger S, Hopper JL, Potter J, de la Chapelle A, Vasen HF, Dunlop MG, Thibodeau SN, Jenkins MA.

J Natl Cancer Inst. 2010 Feb 3;102(3):193-201. doi: 10.1093/jnci/djp473. Epub 2009 Dec 22.

49.

HLA-DR expression is associated with better prognosis in sporadic Australian clinicopathological Stage C colorectal cancers.

Walsh MD, Dent OF, Young JP, Wright CM, Barker MA, Leggett BA, Bokey L, Chapuis PH, Jass JR, Macdonald GA.

Int J Cancer. 2009 Sep 1;125(5):1231-7. doi: 10.1002/ijc.24484.

50.

Classifying MLH1 and MSH2 variants using bioinformatic prediction, splicing assays, segregation, and tumor characteristics.

Arnold S, Buchanan DD, Barker M, Jaskowski L, Walsh MD, Birney G, Woods MO, Hopper JL, Jenkins MA, Brown MA, Tavtigian SV, Goldgar DE, Young JP, Spurdle AB.

Hum Mutat. 2009 May;30(5):757-70. doi: 10.1002/humu.20936.

Supplemental Content

Loading ...
Support Center